Willingness to Pay for a Quality-adjusted Life Year
Tóm tắt
Cost-benefit analysis (CBA) provides a clear decision rule: undertake an intervention if the monetary value of its benefits exceed its costs. However, due to a reluctance to characterize health benefits in monetary terms, users of cost-utility and cost-effectiveness analyses must rely on arbitrary standards (e.g., < $50,000 per QALY) to deem a program "cost-effective." Moreover, there is no consensus regarding the appropriate dollar value per QALY gained upon which to base resource allocation decisions. To address this, the authors determined the value of a QALY as implied by the value-of-life literature and compared this value with arbitrary thresholds for cost-effectiveness that have come into common use. A literature search identified 42 estimates of the value of life that were appropriate for inclusion. These estimates were classified by method: human capital (HK), contingent valuation (CV), revealed preference/job risk (RP-JR) and revealed preference/non-occupational safety (RP-S), and by U.S. or non-U.S. origin. After converting these value-of-life estimates to 1997 U.S. dollars, the life expectancy of the study population, age-specific QALY weights, and a 3% real discount rate were used to calculate the implied value of a QALY. An ordinary least-squares regression of the value of a QALY on study type and national origin explained 28.4% of the variance across studies. Most of the explained variance was attributable to study type; national origin did not significantly affect the values. Median values by study type were $24,777 (HK estimates), $93,402 (RP-S estimates), $161,305 (CV estimates), and $428,286 (RP-JR estimates). With the exception of HK, these far exceed the "rules of thumb" that are frequently used to determine whether an intervention produces an acceptable increase in health benefits in exchange for incremental expenditures. Key words: cost-effectiveness analysis; cost-utility analysis; quality-adjusted life years; value of life. (Med Decis Making 2000;20:332-342)
Từ khóa
Tài liệu tham khảo
Gafni A, 1993, Can Med Assoc J, 148, 913
Laupacis A, 1992, Can Med Assoc J., 146, 473
Weinstein MC, 1995, From cost-effectiveness ratios to resource allocation: where to draw the line?
U.S. Renal Data System., 1998, USRDS 1998 Annual Data Report
Cooper BS, 1976, Social Security Bulletin, 39, 21
Desaigues B, Rabl A. Reference values for human life an economic analysis of a continguent valuation in France In. Schwab Christe NG, Soguel NC. (eds). Contingent Valuation, Transport Safety and the Value of Life Boston, MA: Kluwer Academic Publishers , 1995; 85-112.
Kidholm K. Assessing the value of traffic safety using the contingent valuation technique: the Danish survey In: Schwab Christe NG, Soguel NC (eds). Contingent Valuation, Transport Safety and the Value of Life. Boston, MA: Kluwer Academic Publishers, 1995:45-61
Max W, 1990, Inquiry, 27, 332
Viscusi WK., 1978, Public Policy, 26, 359
National Center for Health Statistics., 1997, Vital Statistics of the United States, 1993, preprint of Vol. II, mortality, part A sec 6 life tables
Shepard DS, Zeckhauser RJ. Life-cycle consumption and willingness to pay for increased survival In Jones-Lee, MW (ed). The Value of Life and Safety. Geneva, Switzerland North-Holland Publishing Company, 1982;95-141
1993, Valuation Federal Register, 58, 4602